Previous studies have shown that NSCLC PDX models with EGFR exon19 deletion mutation and L858R mutation was sensitive to EGFR TKIs gefitinib, erlotinib, dacomitinib, and afatinib, which was in accordance with the clinical results (20). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.